| Catalog No. | AF004014 |
|---|
| Applications | ELISA |
|---|
| Host species | Rabbit |
|---|
| Isotype | IgG |
|---|
| Clonality | Polyclonal |
|---|
| Immunogen | Cetuximab |
|---|
| Target | Rabbit polyclonal to Erbitux. |
|---|
| Specificity | The product is specific for Cetuximab. This antibody serves as an excellent positive control for Cetuximab immunogenicity (ADA) assays. |
|---|
| Purification | Purified by antigen affinity column. |
|---|
| Accession | 205923-56-4 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300. |
|---|
| Product Usage Information |
| Application |
Dilution |
| ELISA |
1:5000-1:20000 |
| IHC |
1:50-1:500 |
| WB |
1:500-1:2000 |
|
|---|
| Stability and Storage | The product can be stored for 2 - 3 weeks at 2 to 8°C or for up to 12 months at -20°C. Avoid repeated freezing and thawing cycles. |
|---|
| Background | Cetuximab (Erbitux) is a chimeric (mouse/human) monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with metastatic colorectal cancer, metastatic non-small cell lung cancer and head and neck cancer. Cetuximab, as an epidermal growth factor receptor (EGFR) inhibitor, binds to EGFR.
• Polyclonal antibody-induced downregulation of HER1/EGFR and HER2 surpasses the effect of combinations of specific registered antibodies., PMID:36408164
• Polyclonal antitumor immunoglobulin may play a role in ovarian cancer adjuvant therapy., PMID:21255939
|
|---|
| Note | For research use only. |
|---|
